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Introduction
The introduction of monoclonal antibodies for the
treatment of cancer
Monoclonal Antibodies (mAbs) comprise a class of ther-
apeutic biologics that has been increasingly used over
the last decades. The concept of using antibodies to
selectively target tumors was proposed by Paul Ehrlich
over a century ago [1]. The development of the hybri-
doma technology in 1975 enabled the production of
monoclonal antibodies, which contain uniform variable
regions and are thus specific for a single epitope. They
are immunoglobulin molecules secreted from a popula-
tion of identical cells and are homogeneous in structure
and binding specificity. Their specificity for the target,
together with the fact that they are relatively well toler-
ated and have a long half-life has contributed to their
success in drug development.
Antibodies can trigger direct effects on tumor growth
causing apoptosis or inhibition of proliferation, they can
also mediate immune effector functions. The first anti-
bodies used in the clinic were of murine origin. Due to
their immunogenicity in humans and poor ability to
induce human immune effector responses, they exhib-
ited limited clinical applicability. Chimeric, humanized
and fully human monoclonal antibodies have now been
developed to address these problems. Chimeric antibo-
dies are encoded by genes from more than one species,
usually with antigen-binding regions from mouse genes
and constant regions from human genes, while huma-
nized antibodies are genetically engineered mouse anti-
body in which the protein sequence has been modified
to mimic that of human antibodies [1]. Antibodies can
be subdivided into two distinct functional units: the
fragment of antigen binding (Fab) and the constant frag-
ment (Fc). The Fab contains the variable region, which
consists of three hypervariable complementarity-deter-
mining regions (CDRs) that form the antigen binding
site of the antibody and confer antigen specificity. The
Fc can bind to immune effector cells and complement
that can both mediate antibody directed immune killing.
Mechanism of action of monoclonal antibodies for the
treatment of cancer
Altering signal transduction in the downstream intracellular
pathways
Cancer cells express various cell surface receptors that
activate intracellular pathways leading to growth.
Amongst these, EGFR or ErbB1, ErbB2 or HER-2/Neu,
HER-3 and HER-4 are of the same family and are over-
expressed in epithelial malignancies originating from the
colon, breast, lung and head and neck resulting in
rapidly proliferating disease and increased metastatic
potential. Anti-EGFR antibodies bind to the receptor
domain of the EGFR receptor inhibiting the downstream
activation of the receptor and increasing receptor inter-
nalization. These antibodies can inhibit the cancer cell
cycle leading to apoptosis. In addition, the combination
of antibodies with chemotherapy enhances the activity
of chemotherapy. AntiHER-2 antibodies promote recep-
tor internalization and cell cycle arrest. Anti-HER2 anti-
bodies can also block heterodimer formation between
HER-2 and HER-3 or HER-4 providing an additional
mode of action [2].
Antibody-dependent cytotoxicity (ADCC)
This mechanism results in the immune-mediated destruc-
tion of the cancer cells that are coated by antibodies. The
effector cells in the antibody-dependent cytotoxicity
include macrophages, NK cells and neutrophils. ADCC
depends on the Fc portion of the antibody that binds a Fc
gamma receptor (FcgR) on the effector cells. ADCC
occurs when the Fab and Fc portions of the mAb engage
both tumor cell antigen and an activating FcgR, respec-
tively, thus creating a bridge from the tumour cell to the
effector cell. Target cell recognition is then coupled to a
lytic attack on the target cell mounted by effector cells.
Several studies have established the importance of FcgR1Orygen Biotecnologia S.A
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interactions for the in vivo antitumor effects of certain
monoclonal antibodies in murine models and clinical
trials. The antitumor activities of trastuzumab and rituxi-
mab have been shown to be lower in FcgR -deficient mice
than wild-type mice, for example [2]. The role of FcgR in
the antitumor response has been further supported by the
finding that polymorphisms in genes encoding FcgR result
in differential response rates to therapeutic monoclonal
antibodies [3].
Complement-mediated cytotoxicity (CDC)
CDC results from a cytolytic cascade mediated by a series
of complement proteins, resulting in lysis of the anti-
body-bound cell [2]. Antibody ability to bind comple-
ment varies with the Ig isotypes. Interactions with IgM,
IgG1, and IgG3 are strong while IgG2 is a poor inductor
and IgG4 is devoid of complement activation functions.
CDC has been shown to be an important mechanism of
action of rituximab and depletion of complement in
mouse models led to the complete loss of activity of
rituximab [4].
Soluble ligand neutralization
Antibodies can bind to circulating proteins and interfere
with their ability to find their targets to help facilitate
growth of the tumors. One important example of this
mechanism is bevacizumab which is a fully humanized
monoclonal antibody against VEGF-A. Bevacizumab
binds and inactivates the biological activity of VEGF-A,
inhibiting angiogenesis and thus, tumor growth and pro-
liferation [5]. Siltuximab is another monoclonal antibody
that works by ligand neutralization. It binds to IL-6 thus
inhibiting the further action of IL-6 on tumor growth [6].
Cytotoxic drug delivery
Cytotoxic agents can be linked to tumor targeted mono-
clonal antibodies with the aim of delivering them specifi-
cally to the tumors cells [7]. This approach limits systemic
side effects. Two exciting examples of this technology are
trastuzumab-DM1 T-DM1, a HER2 directed antibody
drug conjugate, and brentuximab vedotin, a CD30 directed
antibody drug conjugate [2].
The first generation Several antibodies have been
approved by the FDA for the treatment of a variety of solid
tumors and hematological malignancies (Table 1). Thera-
peutic antibodies targeting the EGFR (epidermal growth
factor receptor) and VEGF (vascular endothelial growth
factor) have been successfully used for treatment of
patients with a variety of solid tumors. Trastuzumab has
also been successfully used in patients with either immuno-
histochemical staining or fluorescence in situ hybridization
positive for HER-2 expression. In the hematologic tumors,
the most successful target has been CD20 on B-lymphocyte
cells [2,8]. In Brazil, biosimilar antibodies are being devel-
oped to provide improved access to the first generation of
anti-cancer antibodies. Those being developed include anti-
bodies against CD20, Her2, EGFR and VEGF-A.
The second generation There are multiple therapeutic
and diagnostic antibodies that are currently under testing
or development [8]. The current pipeline of anticancer
mAbs in clinical studies includes more than 100 candi-
dates. The canonical bivalent, monospecific, full-length
IgG molecule is representative of about half the anticancer
mAbs in the pipeline [9]. The remaining are noncanonical
candidates that are conjugated to drugs or radiolabels,
multispecific molecules or antibodies engineered for
increased functionality, and antibody fragments. Advances
in protein- and glyco-engineering are now enabling the
production of next-generation mAbs that are potentially
more efficacious compared to the first-generation versions.
Although the use of antibodies to guide drugs to a specific
target has been explored for over 30 years, advances in the
knowledge of linker and drug properties, and antibody
engineering, design and selection, have led to the develop-
ment of a new generation of molecules that are demon-
strating promising clinical results [9]. One example is
trastuzumab emtansine, a humanized anti-HER2 antibody
conjugated to DM1 that is undergoing evaluation in Phase
III studies of breast cancer patients [7]. Bispecific antibo-
dies, as the name suggests, are designed to bind two differ-
ent targets. Modifications in protein sequence have been
shown to extend antibody half-life and afucosylated mAbs
are known to have enhanced effector functions [9]. Most
anticancer mAbs kill cells directly by binding to an antigen
associated with a tumor cell and inducing cell death via
effector functions, cytotoxic payloads or blockade of sig-
nals required for growth. However, in the last few years,
antibodies that present indirect mechanisms of action,
such as the activation of the immune system to combat
tumors, have been developed. Ipilimumab, a first in class
T-cell potentiator was approved for treatment of meta-
static melanoma and represents the first therapy demon-
strated to improve overall survival in melanoma [10].
Other advances illustrate how new insights into the struc-
ture and function of receptors allow them to be targeted
in novel ways, with expected improvements in the thera-
peutic efficacy. EGFR is the target for three marketed
anticancer mAbs (cetuximab, panitumumab and nimotu-
zumab) (Table 1). Recently, monoclonal antibody 806
(mAb806) was shown to target a conformational epitope
exposed on wild-type EGFR when it is overexpressed on
tumor cells or induced by the presence of oncogenic
mutations such as EGFRvIII. The mechanism of action of
mAb806, which allows for EGFR inhibition without nor-
mal tissue toxicity, creates opportunities for combination
therapy and strongly suggests mAb806 will be a superior
targeted delivery system for antitumor agents. This con-
cept of conformational epitope targeting by antibodies
reflects an underlying interplay between the structure and
biology of different conformational forms of the EGFR
family [10].
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Conclusions
The number of monoclonal antibodies that have been
approved or are in development for cancer treatment
has been steadily increasing over the last years. Because
of their high target specificity, generally low toxicity and
the ability to activate the immune system, the use of
therapeutic antibodies for cancer treatment is very pro-
mising. They currently provide clinical benefit to
patients with cancer and have been established as ‘stan-
dard of care’ agents for several tumor types. Advances
in the identification and validation of new targets,
manipulation of tumor-host microenvironment interac-
tions, and optimization of antibody structure to promote
anti-tumor immune responses will generate many new
treatments for cancer over the next decade.
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Table 1 Monoclonal antibodies approved for clinical use in oncology
Antibody name Target Antibody format Application
Cetuximab EGFR Chimeric Colorectal, breast and lung cancer
Panitumumab EGFR Human Colorectal cancer
Nimotuzumab EGFR Humanized Head and neck cancer
Rituximab CD20 Chimeric Non-Hodgkin lymphoma
Trastuzumab HER2 Humanized Breast cancer
Alemtuzumab CD52 Humanized Chronic lymphocytic leukemia
Bevacizumab VEGFA Humanized Colorectal and lung cancer
Ofatumumab CD20 Human Chronic lymphocytic leukemia
Ipilimumab CTLA-4 Human Metastatic melanoma
Pertuzumab HER2 Humanized Breast cancer
Denosumab RANK Ligand Human Solid tumor bony metastases
Brentuximab vedotin CD30 Chimeric Hodgkin’s or systemic anaplastic large cell lymphoma
Gemtuzumabozogamicin CD33 Humanized Acute myelogenous leukemia
90Y-Ibritumomab tiuxetan CD20 Mouse Low grade or transformed B cell non-Hodgkin’s lymphoma
Tositumomaband 131I-tositumomab CD20 Mouse Lymphoma
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